HGH fragment 176-191 vs AOD 9604 compared: how these growth hormone peptides differ in structure, half-life, research dosing, and legal status.
HGH fragment 176-191 and AOD 9604 are closely related but not identical peptides. Both are built from the C-terminal tail of human growth hormone — the last 16 amino acids, residues 176 through 191 — and both are researched for effects on fat metabolism rather than for growth. AOD 9604 is a stabilized synthetic analog of that same fragment, which is why the two are constantly compared even though they are not interchangeable.
The practical takeaway: AOD 9604 is the modified, longer-acting version that has been tested in human clinical trials, while HGH fragment 176-191 is the unmodified natural sequence whose research is mostly preclinical. Neither is approved by the FDA for human use in the United States.
What Is HGH Fragment 176-191?
HGH fragment 176-191 is a 16-amino-acid peptide that matches the tail end of the human growth hormone molecule. Researchers isolated it because this region appears to drive lipolysis — the breakdown of stored fat — without engaging the growth hormone receptor itself.
That distinction matters. Full growth hormone raises IGF-1 and can affect blood glucose, but the 176-191 fragment does not appear to do either in published studies. Commonly cited hgh fragment 176 191 benefits in the research literature include increased fat breakdown and reduced fat storage, which is why it is often discussed as a "fat-loss only" peptide.
Its main practical drawback is a short half-life. Most research protocols split the dose across two or three subcutaneous injections per day, often timed around fasting windows.
What Is AOD 9604?
AOD 9604 is a synthetic peptide developed in Australia by Metabolic Pharmaceuticals as a modified version of the same HGH 176-191 fragment. The key change is an added tyrosine residue at the N-terminus, which makes the molecule more stable and resistant to breakdown in the body.
Because of that modification, AOD 9604 lasts longer and is usually researched as a single daily dose. It moved further into formal drug development than the unmodified fragment, reaching phase IIB human trials for obesity before the program was discontinued in the late 2000s.
AOD 9604 has also been explored for cartilage repair and osteoarthritis in early research. It is now widely sold as an oral spray or capsule, even though human oral absorption data is limited.
HGH Fragment 176-191 vs AOD 9604: Side-by-Side
Most people researching aod 9604 vs hgh frag 176-191 are trying to decide whether the modified peptide is worth the extra cost.
| Feature | HGH Fragment 176-191 | AOD 9604 |
|---|---|---|
| Structure | 16-amino-acid C-terminal tail of human growth hormone (residues 176-191) | Same core fragment plus an added N-terminal tyrosine for stability |
| Relationship | The original, unmodified sequence | Synthetic analog of the 176-191 fragment |
| Half-life | Short; often researched two to three times daily | Longer; usually researched once daily |
| Typical research dose | 250-500 mcg per injection | About 300 mcg once daily |
| Human trial data | Limited; mostly animal and small studies | Multiple human obesity trials with modest results |
| FDA status | Not approved for human use | Not approved for human use |
| WADA status | Prohibited as a growth hormone-related peptide | Specifically named on the Prohibited List |
| Common forms | Lyophilized powder for injection | Injectable powder; also sold as oral sprays and capsules |
What the Research Actually Shows
AOD 9604 is the better-studied of the two. In human trials, participants typically lost modest amounts of fat mass, and the results were not strong enough to justify continued drug development. Some trials found no meaningful difference from placebo on key endpoints.
Evidence for HGH fragment 176-191 is thinner. Much of it comes from rodent studies and small human experiments, and no large randomized trial shows that it produces significant weight loss on its own.
Neither peptide is a substitute for a calorie deficit, and neither has been shown to produce the kind of weight loss associated with modern prescription obesity drugs. The aod 9604 vs retatrutide comparison makes this clear: retatrutide is an investigational triple-agonist with large trial data behind it, while AOD 9604 is a discontinued development candidate now sold as a research chemical.
Prescription options differ just as sharply. Looking at aod 9604 vs tesamorelin, tesamorelin is FDA-approved for HIV-associated lipodystrophy, while AOD 9604 has no approved indication anywhere. The hgh fragment 176-191 vs somatropin comparison also comes down to receptor activity: somatropin is full recombinant growth hormone that raises IGF-1 and can affect blood sugar, while the fragment was designed to avoid those effects.
Dosing and Half-Life Differences
Dosing is one of the clearest practical differences between the two peptides.
- HGH fragment 176-191: commonly researched at 250-500 mcg per dose, two to three times daily, usually injected subcutaneously and often timed around fasting.
- AOD 9604: most protocols use roughly 300 mcg once daily, a schedule made possible by the modifications that extend the peptide's half-life.
Neither schedule is established medical guidance. These numbers come from research protocols and vendor recommendations, not from FDA-reviewed labeling, and dose information circulating in forums should be treated with skepticism.
Safety, Legality, and Sourcing
Neither peptide is FDA-approved for human use in the United States. AOD 9604 is specifically named on the World Anti-Doping Agency Prohibited List, and growth hormone fragments more broadly fall under WADA's peptide hormone category, which makes both substances risky for any tested athlete.
Because these products are sold as research chemicals, purity and sterility are not guaranteed. Independent testing of gray-market peptides has repeatedly found mislabeled vials, underdosed products, and contamination. Injectable peptides bought online carry infection risk when they are not sterile.
Reported side effects in trials and user reports include injection-site reactions, headaches, and fatigue. Long-term safety data for both compounds is essentially absent. Anyone considering either peptide should talk with a licensed healthcare professional first, especially people with diabetes, thyroid conditions, or a history of cancer.
One common mix-up is worth clearing up: AOD 9604 is not hCG. The two were confused in Australian media coverage years ago because of a naming error, and that mistake still circulates online. AOD 9604 is a growth hormone fragment analog, not a pregnancy hormone.
Frequently Asked Questions
Is AOD 9604 the same thing as HGH fragment 176-191?
They are closely related but not identical. AOD 9604 is a synthetic analog of the HGH 176-191 fragment with an added tyrosine residue that makes it more stable and longer-acting. The fat-metabolism target is the same, but the two are different molecules with different dosing schedules.
Is AOD 9604 FDA approved for weight loss?
No. AOD 9604 has been tested in human clinical trials, mostly in Australia, but it is not approved by the FDA for weight loss or any other use in the United States. It is sold as a research chemical, and it is named on the WADA Prohibited List.
Which is better for fat loss, HGH fragment 176-191 or AOD 9604?
Neither has strong evidence of meaningful fat loss in humans. AOD 9604 is the only one of the two with published human trials, and those results were modest enough that development stopped. HGH fragment 176-191 rests mostly on animal data, so claims about either peptide should be treated cautiously.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.